Recent findings from a phase I clinical trial of patients with breast cancer treated with atezolizumab (anti-PD-L1) indicate that elevated baseline plasma levels of interleukin 6 (IL-6) and C-reactive protein (CRP) are associated with reduced progression free and overall survival (12). Here, CRP is linked to breast carcinoma.